Author

A. Gomez-Brouchet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:biophysical modeling· 1 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell-cell communication· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

B. Garmy-Susini· 1 shared B. Thibault· 1 shared C. Cayron· 1 shared C. Cintas· 1 shared C. Guyon· 1 shared E. Darbo· 1 shared E. Hirsch· 1 shared E. Mouton-Barbosa· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

B. Garmy-Susini

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ATRX alteration contributes to tumor growth and immune escape in pleomorphic sarcomas

L. Darmusey, G. Perot, N. Thebault, S. Le Guellec, N. Desplat, L. Gaston, L. Delespaul, T. Lesluyes, E. Darbo, A. Gomez-Brouchet, E. Richard, J. Baud, L. Leroy, J. M. Coindre, J.-Y. Blay, F. Chibon

This study shows ATRX mutations in sarcomas promote tumor growth and immune escape by reducing mast cell immunity, suggesting targeting the innate immune system could improve outcomes.

bioRxiv · Oct 23, 2020Cancer Biology

Phosphoproteomics identifies PI3K inhibitor-selective adaptive responses in pancreatic cancer cell therapy and resistance

C. Cintas, T. Douche, Z. Dantes, E. Mouton-Barbosa, M.-P. Bousquet, C. Cayron, N. Therville, F. Pont, F. Ramos-Delgado, C. Guyon, B. Garmy-Susini, P. Cappello, O. Burlet-Schiltz, E. Hirsch, A. Gomez-Brouchet, , J. Guillermet-Guibert

This study identifies adaptive phosphoprotein responses to isoform-selective PI3K inhibitors in pancreatic cancer, showing that combination therapy can overcome resistance.

bioRxiv · Oct 8, 2020Cancer Biology